|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-3-10
|
|
pubmed:abstractText |
There is currently no consensus about the most effective adjuvant therapy for adenocarcinoma of the pancreas. Both gemcitabine and erlotinib have been demonstrated to improve survival in patients with metastatic disease. This study was designed to evaluate the efficacy of gemcitabine and erlotinib as adjuvant therapy, and to explore potential biomarkers associated with response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1534-4681
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1122-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21104328-Adenocarcinoma,
pubmed-meshheading:21104328-Adult,
pubmed-meshheading:21104328-Aged,
pubmed-meshheading:21104328-Aged, 80 and over,
pubmed-meshheading:21104328-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21104328-Chemotherapy, Adjuvant,
pubmed-meshheading:21104328-Deoxycytidine,
pubmed-meshheading:21104328-Female,
pubmed-meshheading:21104328-Humans,
pubmed-meshheading:21104328-Immunoenzyme Techniques,
pubmed-meshheading:21104328-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21104328-Male,
pubmed-meshheading:21104328-Middle Aged,
pubmed-meshheading:21104328-Pancreatectomy,
pubmed-meshheading:21104328-Pancreatic Neoplasms,
pubmed-meshheading:21104328-Quinazolines,
pubmed-meshheading:21104328-Receptor, Epidermal Growth Factor,
pubmed-meshheading:21104328-Survival Rate,
pubmed-meshheading:21104328-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
|
|
pubmed:affiliation |
Department of Surgery, Stony Brook University Hospital, Stony Brook, NY, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
